INSIDER
01Overview02Follow the Money03Daily Brief04Live05Congress06Corporate Insiders07Government Money08Political Influence09Institutions10Washington Network11Follow the Power12Disclosure Clock13AI Investigator14Watchlist
ConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProAccountMethodologyMatch reviewLaunch readiness
Data sources

Public disclosures only. Scores flag unusual patterns and are not evidence of wrongdoing. Not investment advice.

RH CHAIN…
OverviewFollow the MoneyDaily BriefLiveCongressCorporate InsidersGovernment MoneyPolitical InfluenceInstitutionsWashington NetworkFollow the PowerDisclosure ClockAI InvestigatorWatchlistConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProAccountMethodologyMatch reviewLaunch readiness
01Overview02Follow the Money03Daily Brief04Live05Congress06Corporate Insiders07Government Money08Political Influence09Institutions10Washington Network11Follow the Power12Disclosure Clock13AI Investigator14Watchlist
ConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProAccountMethodologyMatch reviewLaunch readiness
OverviewFollow the MoneyDaily BriefLiveCongressCorporate InsidersGovernment MoneyPolitical InfluenceInstitutionsWashington NetworkFollow the PowerDisclosure ClockAI InvestigatorWatchlistConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProAccountMethodologyMatch reviewLaunch readiness
Data sources
SEC FORM 46m ago
HOUSE PTR5m ago
SEC 13F5m ago
ROBINHOOD CHAIN5m ago
Public company

BBTXBambusa Therapeutics, Inc.

CIK 0002044950

EDGAR filingsOpen in network
Disclosed transactions20
Buys / sells2 / 0
Max Insider Score43
Connections5with evidence

BBTX · disclosed activity on price

Disclosed transactions

ScoreActorSecuritySideValueExecutedDisclosedLagSourceEvidence
9
SG
Salvia Investment GmbH10% Owner
BBTXBambusa Therapeutics, Inc.
Derivative conversion
C—
3.14M sh
Nov 2, 2026Nov 2, 2026
traded Nov 2, 2026
+0dSEC FORM 4

Evidence

Verified connections

  • In industryevidence
    Pharmaceuticals, devices & health servicesSEC SIC 2836 · Biological Products, (No Diagnostic Substances) · Nov 4, 2026
  • ← Insider ofevidence
    Salvia Investment GmbH10% Owner · Nov 2, 2026
  • ← Insider ofevidence
    Xu ShanshanDirector, See remarks, 10% Owner · Nov 2, 2026
  • ← Insider ofevidence
    MiNeng, Inc.10% Owner · Nov 2, 2026
21
SG
Salvia Investment GmbH10% Owner
BBTXBambusa Therapeutics, Inc.
Derivative conversion
C
—
4.77M sh
Nov 2, 2026
Nov 2, 2026
traded Nov 2, 2026
+0d
SEC FORM 4

Evidence

43
SG
Salvia Investment GmbH10% Owner
BBTXBambusa Therapeutics, Inc.
Open-market purchase
BUY$6.00M
375.0K sh
Nov 2, 2026Nov 2, 2026
traded Nov 2, 2026
+0dSEC FORM 4

Evidence

9
SG
Salvia Investment GmbH10% Owner
BBTXBambusa Therapeutics, Inc.
Derivative conversion
C—
1.47M sh
Nov 2, 2026Nov 2, 2026
traded Nov 2, 2026
+0dSEC FORM 4

Evidence

9
SG
Salvia Investment GmbH10% Owner
BBTXBambusa Therapeutics, Inc.
Derivative conversion
C—
160.9K sh
Nov 2, 2026Nov 2, 2026
traded Nov 2, 2026
+0dSEC FORM 4

Evidence

9
XS
Xu ShanshanDirector, See remarks, 10% Owner
BBTXBambusa Therapeutics, Inc.
Derivative conversion
C—
147.2K sh
Nov 2, 2026Nov 2, 2026
traded Nov 2, 2026
+0dSEC FORM 4

Evidence

9
XS
Xu ShanshanDirector, See remarks, 10% Owner
BBTXBambusa Therapeutics, Inc.
Derivative conversion
C—
4,155 sh
Nov 2, 2026Nov 2, 2026
traded Nov 2, 2026
+0dSEC FORM 4

Evidence

9
XS
Xu ShanshanDirector, See remarks, 10% Owner
BBTXBambusa Therapeutics, Inc.
Derivative conversion
C—
10.4K sh
Nov 2, 2026Nov 2, 2026
traded Nov 2, 2026
+0dSEC FORM 4

Evidence

9
XS
Xu ShanshanDirector, See remarks, 10% Owner
BBTXBambusa Therapeutics, Inc.
Derivative conversion
C—
1,753 sh
Nov 2, 2026Nov 2, 2026
traded Nov 2, 2026
+0dSEC FORM 4

Evidence

9
XS
Xu ShanshanDirector, See remarks, 10% Owner
BBTXBambusa Therapeutics, Inc.
Derivative conversion
C—
37.4K sh
Nov 2, 2026Nov 2, 2026
traded Nov 2, 2026
+0dSEC FORM 4

Evidence

9
XS
Xu ShanshanDirector, See remarks, 10% Owner
BBTXBambusa Therapeutics, Inc.
Derivative conversion
C—
94.0K sh
Nov 2, 2026Nov 2, 2026
traded Nov 2, 2026
+0dSEC FORM 4

Evidence

9
XS
Xu ShanshanDirector, See remarks, 10% Owner
BBTXBambusa Therapeutics, Inc.
Derivative conversion
C—
15.8K sh
Nov 2, 2026Nov 2, 2026
traded Nov 2, 2026
+0dSEC FORM 4

Evidence

9
XS
Xu ShanshanDirector, See remarks, 10% Owner
BBTXBambusa Therapeutics, Inc.
Grant or award
A—
379.1K sh
Oct 29, 2026Nov 2, 2026
traded Oct 29, 2026
+4dSEC FORM 4

Evidence

9
XS
Xu ShanshanDirector, See remarks, 10% Owner
BBTXBambusa Therapeutics, Inc.
Grant or award
A—
758.2K sh
Oct 29, 2026Nov 2, 2026
traded Oct 29, 2026
+4dSEC FORM 4

Evidence

21
JW
Jeggle Helmut WolfgangDirector, 10% Owner
BBTXBambusa Therapeutics, Inc.
Derivative conversion
C—
4.77M sh
Nov 2, 2026Nov 2, 2026
traded Nov 2, 2026
+0dSEC FORM 4

Evidence

43
JW
Jeggle Helmut WolfgangDirector, 10% Owner
BBTXBambusa Therapeutics, Inc.
Open-market purchase
BUY$6.00M
375.0K sh
Nov 2, 2026Nov 2, 2026
traded Nov 2, 2026
+0dSEC FORM 4

Evidence

9
JW
Jeggle Helmut WolfgangDirector, 10% Owner
BBTXBambusa Therapeutics, Inc.
Derivative conversion
C—
3.14M sh
Nov 2, 2026Nov 2, 2026
traded Nov 2, 2026
+0dSEC FORM 4

Evidence

9
JW
Jeggle Helmut WolfgangDirector, 10% Owner
BBTXBambusa Therapeutics, Inc.
Derivative conversion
C—
1.47M sh
Nov 2, 2026Nov 2, 2026
traded Nov 2, 2026
+0dSEC FORM 4

Evidence

9
JW
Jeggle Helmut WolfgangDirector, 10% Owner
BBTXBambusa Therapeutics, Inc.
Derivative conversion
C—
160.9K sh
Nov 2, 2026Nov 2, 2026
traded Nov 2, 2026
+0dSEC FORM 4

Evidence

9
XS
Xu ShanshanDirector, See remarks, 10% Owner
BBTXBambusa Therapeutics, Inc.
Derivative conversion
C—
16.4K sh
Nov 2, 2026Nov 2, 2026
traded Nov 2, 2026
+0dSEC FORM 4

Evidence

  • ← Insider ofevidence
    Jeggle Helmut WolfgangDirector, 10% Owner · Nov 2, 2026